Lotus Pharmaceutical (“Lotus”) and Alvogen today announced the launch of the first generic equivalent of RevlimidTM (lenalidomide) in some of their CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and will be launched globally from 2019 onwards. It is a fully generic and bioequivalent version of RevlimidTM capsules and has been fully developed in-house at Lotus to be marketed globally.
Petar Vazharov, General Manager of Lotus and Executive Vice President at Alvogen in the APAC region, commented:
Hacho Hatchikian, Executive Vice President at Alvogen in the CEE regions, added:
RevlimidTM is indicated for the treatment of various oncology diseases including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. By the time of Alvogen launch, RevlimidTMis perceived as the single biggest-selling oncology drug with approximately $9.8 billion sales globally. Lotus currently has more than 10 oncology products in development and pending approval globally.